Obinutuzumab: First Global Approval

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

(2013) J. Radford et al.   BLOOD

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Gilles A. Salles et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

(2013) S. Rafiq et al.   JOURNAL OF IMMUNOLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

(2012) J. Honeychurch et al.   BLOOD

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

(2012) L. H. Sehn et al.   BLOOD

Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

(2012) Michinori Ogura et al.   CANCER SCIENCE

Advances in the management of follicular lymphoma

(2012) Till M. Seiler et al.   CURRENT OPINION IN ONCOLOGY

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Current Status of Targeted Therapies for Mantle Cell Lymphoma

(2011) Julie E. Chang et al.   DRUGS

Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia

(2011) Valentin Goede et al.   DRUGS & AGING

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-β receptor II dominant negative mice

(2009) Yuki Moritoki et al.   HEPATOLOGY